We demonstrate the use of representational difference analysis for cloning probes that detect DNA loss and amplification in tumors. Using DNA isolated from human tumor cell lines to drive hybridization against matched normal DNA, we were able to identify six genomic regions that are homozygously deleted in cultured cancer cells. When this method was applied in the reverse way, using normal DNA to drive hybridization against tumor cell DNA, we readily isolated probes detecting amplification. Representational difference analysis was also performed on DNAs derived from tumor biopsies, and we thereby discovered a probe detecting very frequent homozygous loss in colon cancer cell lines and located on chromosome 3p.
A variety of genetic lesions are found in tumors, including rearrangement, gene amplification, point mutation, deletion, and acquisition of viral genomes (1, 2) . Delineating the genes involved has often led to important new insights into the pathophysiology of cancer. Therefore, efficient methods for the discovery of new genetic lesions in tumors may accelerate our management of that disease. Recently we described a method, called representational difference analysis (RDA) , for analyzing the differences between complex but highly related genomes (3) .
RDA combines three elements: representation, subtractive enrichment, and kinetic enrichment. The procedure is carried out in two stages. The first comprises the preparation of representations for driver and tester DNAs, during which small restriction endonuclease fragments (called ARFs) are ligated to oligonucleotide adapters and amplified by the polymerase chain reaction (PCR). The second stage is comprised of the reiterative hybridization/selection steps. Prior to the hybridization/selection step, only tester molecules are fitted with a new pair of defined oligonucleotides at their 5' ends. After reannealing tester and driver, the mixture of molecules is treated with DNA polymerase. This adds the complement of the defined oligonucleotides to both 3' ends of only self reannealed tester DNA fragments. When the defined oligonucleotide is used as primer in PCR of the mixture, such molecules can participate in exponential amplification. This serves three purposes. (i) Molecules of tester that reanneal to the excess of driver are "subtracted out" since the heteroduplexes they form with driver have the primer complement on one end only, thus leading to inefficient, linear amplification of only one strand. (ii) Abundant sequences of tester will reanneal faster than less abundant ones (kinetic enrichment) so that sequences that are enriched or amplified become even more enriched. (iii) PCR amplification increases the yield so that the hybridization/selection step can be reiterated or the product can be cloned and analyzed. Two of
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RDA may be used in two ways. MATERIALS AND METHODS Cell Lines and DNA Samples. Renal cell carcinoma (RCC) cell lines UOK112, UOK114, UOK124, UOK132, UOK108, UOK111, UOK127, UOK146, and UOK154 and normal DNAs from the same patients were obtained as described (4 (7) . To sublocalize probes on chromosome 3, DNA from hybrid clone GM 11102 retaining the der(3) t(3;16) (ql3.2;ql3) chromosome was used (NIGMS Human Genetic Mutant Cell Repository). Fluorescence in situ hybridization (FISH) was performed as described (9) . RESULTS Tumor DNA as Driver. We performed RDA on 16 individual pairs of tumor DNAs (used as driver) and matched normal DNAs (used as tester) derived from the same patient, as otherwise cloning of polymorphic differences between different individuals predominates. In all cases, we used Bgl II as the restriction endonuclease to prepare representations. Pure tumor DNAs were isolated from 15 tumor cell lines (including 9 RCCs and 6 colon cancer cell lines), and normal DNA was derived from unaffected blood or tissue but not from EBVimmortalized cell lines lest viral DNA fragments be cloned. In one case we used a fluorescence-activated cell sorter to fractionate nuclei from an esophageal cancer biopsy into aneuploid and diploid fractions that were used for preparation of driver and tester DNA, respectively.
In each application of RDA, 2-13 difference products were observed and cloned into plasmids. Plasmid clones were picked at random and inserts of different sizes were analyzed by hybridization to blots containing representations from the normal (tester) and tumor (driver) DNAs, as well as Bgl II Proc. Natt Acad Sci USA 92 (1995) representations of normal male and female DNAs. The "informative" probes, which were hybridizing to one band on a blot, and were absent in the driver representation, were taken for further analysis, except for those that derived from the Y chromosome (loss of the Y chromosome information was frequently observed in RCCs). In search for clones detecting single copy sequences that are frequently lost in tumors, informative probes were hybridized to blots containing Bgl II-digested DNAs from a standard blotting panel of human tumor cell lines. Those probes that were commonly polymorphic at Bgl II sites were presumed to have arisen by loss of heterozygosity (LOH) and were not further studied unless they did not detect any bands in at least one tumor DNA on a blot. Probes of this type, as well as the remaining nonpolymorphic single copy probes, were sequenced, and oligonucleotides derived from the sequence were synthesized to be used for PCR screening of total genomic DNA from tester, driver, and panels of human tumor cell lines. When we could not detect probe sequences in the genomic DNA that was used as driver, we generally assumed that the probe detected homozygous deletion. All probes absent in two or more DNA samples from standard PCR panel were hybridized to allele frequency blots containing Bgl II digests of human DNAs from various races. This way we were able to find two probes that did not hybridize to any sequences in several normal human DNAs. We thus presume that these two probes actually detect hemizygous loss of a deletion polymorphism (see Table 1 , footnote t). Tables   1 and 2 summarize all of our results obtained using tumor DNA as driver.
Typical results and analysis are shown in Fig. 1 . In this particular case, RDA was performed using DNA from the RCC cell line UOK146 as driver. One of the probes (UOK146-8) cloned from the third round of hybridization/ selection (Fig. 1A, lane c) was found to be absent in the Bgl II representation of the tumor DNA. It was further analyzed by Southern blotting and PCR ( Fig. 1 B and C, respectively) , indicating its frequent homozygous loss in many tumor cell lines. Subsequent PCR analysis of driver and tester DNAs indicated that UOK146-8 in fact detected loss of a small allele of a rare Bgl II polymorphism in the cell line UOK146 (data not shown) and was present in the difference product due to LOH rather than homozygous loss in the original tumor. Probe UOK146-8 represents one of three probes detecting apparent homozygous loss in at least one tumor source but isolated by virtue of LOH in the original tumor (see Table 2 ).
All probes that detected homozygous loss in at least one tumor cell line were mapped to human chromosomes using a panel of monochromosomal human/rodent somatic cell hy- brids (see Materials and Methods). In two cases, an additional human/rodent hybrid was used to resolve location to 3p or 3q (see Table 2 ).
Tumor DNA as Tester. We also used RDA by taking DNA from tumor cell lines as tester and DNA from matched normals as driver. The cell lines used were melanoma (AHMel), small cell carcinoma of the lung (NCI H1770, gift of John Minna), and two RCC cell lines (UOK161 and UOK124). In two cases (AH-Mel and NCI H1770) difference products were observed and were discernible even after the first round of hybridization/selection. In each of these cases individual products cloned from the second round of hybridization/selection detected high-level amplifications (30-to 100-fold) in the tumor DNA used as tester. Additionally, RDA products from NCI H1770 were found to be amplified in a neuroblastoma cell line, IMR-5. The sequences from NCI H1770 were mapped to chromosome 2, and those from AH-Mel were mapped to chromosome 3. The entirety of the RDA product from the second round of hybridization/selection of the melanoma tumor cell line was used as a probe for FISH to metaphase preparations from the AH-Mel cell line. Two and in some cases three homogeneously staining regions were readily observed in tumor cells with this probe (see Fig. 2 ).
The presence of amplified sequences from tumors in the RDA product even after one round of hybridization/selection suggested to us that such difference products would dominate over single copy sequence differences and hence that the detection of gene amplification might not require matched tumor and normal DNAs. To test this idea, we took AH-Mel DNA as tester and either a single or pooled DNA from 10 unrelated humans as driver. In either case, RDA products were observed even after one round of hybridization/ selection, and difference products obtained after the second round were found to map to the same amplified region in AH-Mel as the RDA products found using the matched normal DNA as driver.
DISCUSSION
The RDA methodology may be successfully applied to the analysis of genetic lesions in tumors in two formats. In the first format, the use of tumor DNA as driver and normal DNA as tester leads to the discovery of probes that detect "loss" of information in tumors: in the present cases, LOH, hemizygous loss, and homozygous loss. Such losses may indicate the loss of function of a "tumor suppressor" gene, or a set of such genes, that in some way contributes to the evolution of the neoplastic population in its host. When tumor DNA was used as driver, 58 of 83 RDA products were informative-that is, detected loss of genetic information in the tumor source under analysis-and all 16 RDA comparisons of tumor and normal pairs yielded informative probes. In the second format, the use of tumor DNA as tester and normal DNA as driver leads to the discovery of probes that detect "gain" of information in tumors: in the present cases, DNA amplification. Such We must take these numbers with caution because we have not proven that the six probes that detect complete loss in the tumor genome truly arose by homozygous loss. Some of these might represent hemizygous loss at undetected rare deletion polymorphisms. In fact, we expect that some deletion polymorphisms, being recessive organismic lethals, would not be found in the human population in the homozygous state but could occur in tumors by LOH if they were not cell lethals.
Of the total nine probes that detect homozygous loss, probes UOK132-12 and UOK146-8 probably detect the region on chromosome 9 previously known to undergo frequent homozygous loss; and the two probes from VACO 441 both derive from the vicinity of the DCC locus on chromosome 18 (unpublished data), a region previously known to undergo LOH. One probe, derived from the Barrett esophagus biopsy (BE758-6), that detects frequent homozygous loss in colon Proc-Natt Acad Sci USA 92 (1995) cancer and other cell lines, does not yet appear to map to a known tumor suppressor locus (unpublished data). This probe maps to 3p, and intensive study of the surrounding genomic region is necessary. The other probes detect homozygous deletion in at most two cell lines and do not yet appear to coincide with known loci.
When tumor DNA is used as tester, RDA has the potential to detect several types of genetic alterations, including the presence of viral genomes, genomic rearrangements, and a very small proportion of point mutations. Such genetic changes can give rise to restriction endonuclease fragments present in tumor that are not present in the matched normal DNA. In the four tumor cell lines investigated here, no probes for lesions of these types were encountered. Rather, RDA yielded probes that detected highly amplified single copy sequences. These probes do not arise because of absolute differences between normal and tumor DNA, but because their relative abundance in tumor has led to their kinetic enrichment during the RDA procedure. For the isolation of highly amplified sequences in tumor DNA, any normal human DNA can be used as driver, providing a means to clone such sequences from any tumor cell. The two regions we found amplified map to chromosomes 2 (from small cell lung cancer) and 3 (from melanoma). The region on chromosome 2 is also found amplified in a neuroblastoma cell line and hence may contain N-myc (11) . Amplification on chromosome 3 has not been previously described.
For the application of RDA to cancer, the source of driver must be relatively free of the unique tester source (5%). While this is not a problem when normal DNA is used as driver, the tumor source for driver preparation should not be derived from unprocessed biopsies because of the presence of contaminating normal stromal elements. Established tumor cell lines are a convenient source of pure DNA, but the tester DNA must come from the normal host, and this source is often no longer available. Moreover, established tumor cell lines may have accumulated genetic alterations that were not present in the original tumor. We have experimented successfully with flow-sorted nuclei from biopsies. This method of separating tumor DNA from normal DNA is based on differences in ploidy, but other methods (e.g., short-term culture and/or separation of tumor cells from normal cells by surface antigens or other properties) might be employed.
RDA will not detect all differences between tumor and normal DNAs. First, only differences in the respective representations can be found. Since a representation is of lower complexity than the genomic DNA from which it derives, not all differences will be represented. Second, since RDA is a PCR-based methodology and multiple cycles of PCR are used (in excess of 80 cycles for the representation and three rounds of hybridization/selection), only the most efficiently amplifiable differences are readily detected. This probably explains the relatively narrow size range (250-350 bp) of the probes we isolated that detect homozygous deletions. Thus cloning the differences between two samples by RDA using a single restriction endonuclease will hardly exhaust all of their abundant differences.
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